AVBP · Categories · Form 4

AVBP - SEC Form 4 insider transactions

ArriVent BioPharma Inc. (AVBP) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for AVBP

• 4h
  SEC Form 4 filed by Director Parsey Merdad

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 4h
  SEC Form 4 filed by Director Peterson Kristine

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 4h
  SEC Form 4 filed by Director Hohneker John

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 4h
  SEC Form 4 filed by Director Nolet Chris

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by Chief Operating Officer Lachapelle Robin

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by President of R&D Lutzker Stuart

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by Chief Financial Officer Kung Winston

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by General Counsel Kastenmayer James Paul

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 138d
  SEC Form 4 filed by President and CEO Yao Zhengbin

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 139d
  Large owner Hillhouse Investment Management, Ltd. sold $12,983,320 worth of shares (555,555 units at $23.37) (SEC Form 4)

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 342d
  Chief Operating Officer Lachapelle Robin exercised 11,153 shares at a strike of $2.28, increasing direct ownership by 9% to 135,736 units (SEC Form 4)

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 367d
  SEC Form 4 filed by Director Parsey Merdad

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 367d
  SEC Form 4 filed by Director Peterson Kristine

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 367d
  SEC Form 4 filed by Director Hohneker John

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 367d
  SEC Form 4 filed by Director Nolet Chris

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 419d
  SEC Form 4 filed by Director Parsey Merdad

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by President and CEO Yao Zhengbin

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by President of R&D Lutzker Stuart

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by Chief Operating Officer Lachapelle Robin

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by Chief Financial Officer Kung Winston

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 493d
  SEC Form 4 filed by General Counsel Kastenmayer James Paul

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 637d
  Chief Operating Officer Lachapelle Robin exercised 27,566 shares at a strike of $3.28, increasing direct ownership by 28% to 124,583 units (SEC Form 4)

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 763d
  SEC Form 4 filed by Hohneker John

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
• 790d
  SEC Form 4 filed by Peterson Kristine

  4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

Other AVBP categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends